Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial

Dustin G. Brown¹, Erica C. Borresen¹, Regina J. Brown²,³ and Elizabeth P. Ryan¹,³*

¹Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80521, USA
²Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO 80045, USA
³University of Colorado Cancer Center, Aurora, CO 80045, USA

(Submitted 28 October 2016 – Final revision received 28 March 2017 – Accepted 11 April 2017)

Abstract
Rice bran (RB) consumption has been shown to reduce colorectal cancer (CRC) growth in mice and modify the human stool microbiome. Changes in host and microbial metabolism induced by RB consumption was hypothesised to modulate the stool metabolite profile in favour of promoting gut health and inhibiting CRC growth. The objective was to integrate gut microbial metabolite profiles and identify metabolic pathway networks for CRC chemoprevention using non-targeted metabolomics. In all, nineteen CRC survivors participated in a parallel randomised controlled dietary intervention trial that included daily consumption of study-provided foods with heat-stabilised RB (30 g/d) or no additional ingredient (control). Stool samples were collected at baseline and 4 weeks and analysed using GC-MS and ultra-performance liquid chromatography-MS. Stool metabolomics revealed 93 significantly different metabolites in individuals consuming RB. A 264-fold increase in β-hydroxyisovalerylcarnitine and 18-fold increase in β-hydroxyisovalerate exemplified changes in leucine, isoleucine and valine metabolism in the RB group. A total of thirty-nine stool metabolites were significantly different between RB and control groups, including increased hesperidin (28-fold) and narirutin (14-fold). Metabolic pathways impacted in the RB group over time included advanced glycation metabolism in the RB group. A total of thirty-nine stool metabolites were signifi cantly different between RB and control groups, including increased hesperidin (28-fold) and narirutin (14-fold). Metabolic pathways impacted in the RB group over time included advanced glycation end products, steroids and bile acids. Fatty acid, leucine/valine and vitamin B6 metabolic pathways were increased in RB compared with control. There were 453 metabolites identiﬁ ed in the RB food metabolome, thirty-nine of which were identiﬁ ed in stool from RB consumers. RB consumption favourably modulated the stool metabolome of CRC survivors and these ﬁ ndings suggest the need for continued dietary CRC chemoprevention efforts.

Key words: Colorectal cancer: Rice bran: Metabolomics: Phytochemicals: Metabolic pathways

Convincing evidence supports that foods rich in phytochemicals and dietary ﬁ bre decrease risk of colorectal cancer (CRC) (1,2,3). With CRC being the third most common cancer in the world with approximately 1–4 million new cases (4), a focus on lifestyle behaviours, especially diet, may be beneﬁ cial for cancer prevention. Dietary ﬁ bre is comprised of NSP that are found in fruits, vegetables, legumes and whole grains (5). Phytochemicals are diverse classes of compounds including, but not limited to, antioxidants, polysaccharides and saponins (6). Whole grains are a rich source of dietary ﬁ bre and phytochemicals that have been studied for cancer chemopreventive properties (5,6). Whole grain brown rice and rice bran (RB) contain multiple unique plant bioactive components (i.e. β-sitosterol, γ-orzanol, vitamin E isoforms, prebiotics and dietary ﬁ bres) that have been shown to inhibit CRC growth (7–10). For example, consuming 30% ﬁ bre from bran had a chemopreventive effect of reduced adenoma burden in mice, equating to approximately 1–2 g/d per kg RB ﬁ bre for human consumption (11). Dietary RB elicits chemopreventive actions via multiple mechanisms, such as inhibition of cyclo-oxygenase 2, induced nitric oxide synthase expression, NF-κB signalling, chromatin condensation and caspase 3 activation, among others (12–14). RB metabolism by gut microﬂ ora may decrease the intestinal pH and increase intestinal SCFA production (15–17). During colonic fermentation, there are distinct interactions between host and microbial metabolism, resulting in production of secondary metabolites that originated from RB intake (18). Modulation of substrates available to gut microbiota from the diet can inﬂ uence the type and amount of microbial metabolites produced, and was correlated with various health outcomes, including cancer (19). Despite the established dietary chemopreventive actions of RB, a knowledge gap remains of the proﬁ le of RB.

Abbreviations: AGE, advanced glycation end product; CRC, colorectal cancer; RB, Rice bran; UPLC, ultra-performance liquid chromatography.

* Corresponding author: E. P. Ryan, email E.P.Ryan@colostate.edu
small molecules that reach the colon and that work in an additive or synergistic manner to promote healthy metabolism and gastrointestinal function.

Clinical trials established the feasibility of increased consumption of heat-stabilised RB in people and showed that RB intake can modulate the human stool microbiome. These studies helped determine what phytochemicals from RB interact for enhanced microbial metabolism in the colon and excretion in stool. The objective of this study was to integrate gut microbial metabolite profiles and identify metabolic pathway networks for CRC chemoprevention using non-targeted metabolomics. We hypothesised that stool metabolites resulting from both host and microbial metabolism following dietary RB intake represent viable, chemopreventive agents for inhibition of colonic inflammation and CRC recurrence. Results from this study have important dietary implications for prevention of primary and secondary CRC recurrence in adults.

Methods

Study population and stool sample collection

CRC survivors were recruited and enrolled in a parallel randomised controlled dietary intervention trial (NCT01929122) as previously described. In brief, CRC survivors were deemed eligible if they were a healthy adult with a history of CRC, a minimum of 4 months post-cancer treatment, able to follow a dietary intervention for 28 d, had no history of food allergies or major dietary restrictions, and had a BMI between 25 and 35 kg/m². Participants consumed study-provided foods which included one meal and one snack each day. All study meals and snacks were calorically matched across study groups and previously described as including either 30 g/d of heat-stabilised RB or no additional ingredient (control). The addition of 30 g RB to the meal and snack provided 397 kJ (95 kcal) and 6 g of total dietary fibre daily. The consumption of one study meal and snack each day ranged between approximately 2656 and 2929 kJ/d (650 and 700 kcal/d), about one-third of total energy content consumed daily. The remaining two-thirds of daily energy content, approximately 5858 kJ (1400 kcal), was not controlled and was analysed accordingly.

CRC survivors were recruited and enrolled in a parallel randomised controlled dietary intervention trial (NCT01929122) as previously described. In brief, CRC survivors were deemed eligible if they were a healthy adult with a history of CRC, a minimum of 4 months post-cancer treatment, able to follow a dietary intervention for 28 d, had no history of food allergies or major dietary restrictions, and had a BMI between 25 and 35 kg/m². Participants consumed study-provided foods which included one meal and one snack each day. All study meals and snacks were calorically matched across study groups and previously described as including either 30 g/d of heat-stabilised RB or no additional ingredient (control). The addition of 30 g RB to the meal and snack provided 397 kJ (95 kcal) and 6 g of total dietary fibre daily. The consumption of one study meal and snack each day ranged between approximately 2656 and 2929 kJ/d (650 and 700 kcal/d), about one-third of total energy content consumed daily. The remaining two-thirds of daily energy content, approximately 5858 kJ (1400 kcal), was not controlled and was analysed accordingly with the participant’s typical dietary intake. To track all foods consumed, participants recorded dietary intakes using 3-d food logs, which included recorded weights of the study-provided foods. These food logs were analysed using Nutrition ProTM (Axxya Systems) and nutrition results have been previously reported.

This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human participants were approved by Poudre Valley Hospital/University of Colorado Health – North Institutional Review Board (Protocol no. 10-1038) and Colorado State University Institutional Review Board (Protocol no. 09-152014). Written informed consent was obtained from all participants. Stratified randomisation was completed based on sex, BMI and energy intake and participants were randomised into either a control diet group or RB diet group. Study-provided meals and snacks were coded to ensure participants remained blinded to their diet group. The study took place at the University of Colorado Health – North Cancer Center in Fort Collins, CO, between August 2010 and December 2014. Participants self-collected stool samples in specimen containers at two time points: baseline and week 4. Stool samples were lyophilised, aliquoted and stored at −80°C before metabolite extraction. The online Supplementary Fig. S1 illustrates the study flow.

Heat-stabilised rice bran for dietary intervention and metabolomics

The US Department of Agriculture–Rice Research Center provided the heat-stabilised RB used in this study. Rice paddy was milled using standard milling processes to isolate bran. Following milling, RB was heat-stabilised at 110°C for 3 min and stored at −20°C. For this study, Neptune and Dixiebell varieties were chosen due to agronomic similarities and incorporated into study meals and snacks and their nutritional composition has been previously described. For RB food metabolome determination, 100 mg of RB was subjected to non-targeted metabolite profiling at Metabolon. RB was extracted with 80% methanol as previously described, and analysed by GC-MS and ultra-performance liquid chromatography-MS (UPLC-MS/MS) in the positive and negative ionisation mode platforms.

Stool extractions for metabolomics

Stool samples were extracted for metabolite profile evaluation by Metabolon Inc. as previously described. Stool samples were extracted using 80% methanol. The final extract was divided into four aliquots for: UPLC-MS/MS Positive Ion Mode, UPLC-MS/MS Negative Ion Mode, GC-MS and backup.

GC-MS

Samples were derivatised under N₂ using bistrimethylsilyl trifluoroacetamide and separated on a 5% diphenyl/95% dimethyl polysiloxane fused silica column (20 m × 0.18 mm ID; 0.18 µm film thickness) with He as carrier gas and a temperature ramp from 60 to 340°C in a 17.5 min period. Internal standards: amylolzane, 1-phenylhexane, 1-phenyloctane, 1-phenylecdecane, 1-phenyldodecane, hexadecylbenzene, octadecylbenzene, tetradecylbenzene and 2,6-di-tert-butyphenol were added to each sample (250 ng of each standard per sample). Samples were analysed on a Thermo-Finnigan Trace DSQ fastscanning single-quadrupole mass spectrometer using electron impact ionisation and operated at unit mass resolving power. The scan range was from 50 to 750 m/z.

Ultra-performance liquid chromatography-MS

The UPLC-MS/MS portion of the platform was based on a Waters ACQUITY UPLC and a Thermo-Finnigan LTQ MS operated at nominal mass resolution, which consisted of an electrospray ionisation source and linear ion-trap mass analyser. The dried sample extract was reconstituted in acidic or basic UPLC-compatible solvents, each of which contained eleven to thirteen injection standards at fixed concentrations. One aliquot was analysed using acidic ten positive ion-optimised...
Metabolic pathway networks and analysis

To visualise relevant networks of metabolic pathways from stool metabolites, the relative abundances were uploaded into a pathway analysis software and metabolite classification system called Metabolync (portal.metabolon.com). Pathway impact scores were calculated as previously described, and takes into account the number of significantly different compounds in a pathway with all metabolites identified\(^\text{23}\). A score \(\geq 2\) indicates significant alterations of a metabolic pathway when compared with other pathways. Metabolites were visualised via Cytoscape version 2.8.3. Each metabolite was represented by a closed, coloured node extending from a sub-metabolic pathway node (via pathway enrichment score), which connect to a super-metabolic pathway hexagonal node. A node coloured red represents metabolites with significantly higher expression at 4 weeks compared with baseline \((P \leq 0.05)\). A node coloured dark green represents metabolites with significantly lower expression at 4 weeks compared with baseline. Nodes coloured pink or light green represent metabolites trending towards significance with higher expression at 4 weeks and lower expression at 4 weeks, respectively \((0.05 < P \leq 0.1)\). Node size is proportional to fold change magnitude over the 4-week time period for RB diet group.

Statistical analyses

RB and stool metabolite profiles from CRC survivors were quantified in terms of relative abundance and median scaled to 1 as previously described\(^\text{15}\). Metabolomics as an endpoint can be difficult to calculate power due to the complexity of metabolomics studies, including the constant expansion of metabolite libraries and the large number of metabolites identified. There are currently no accepted methods for sample size calculations\(^\text{26,27}\). However, a previous trial in seven healthy adults with no history of CRC, with four participants consuming RB found detectable stool metabolome changes\(^\text{15}\). Thus, a sample group of approximately ten is a reasonable sample size to detect significant changes.

Statistics were performed in ArrayStudio (Omicsoft), GraphPad Prism 6.06 and SAS version 9.4. \(P\) values of \(\leq 0.05\) were statistically significant. A matched-pairs two-way ANOVA with post-test contrasts was completed using the scaled relative abundance of each metabolite to evaluate the impact of dietary RB supplementation over 4 weeks’ time and with regards to changes in the stool metabolome. An estimate of false discovery rate \((q\) value\) was calculated to determine false discoveries common to multiple-comparison-based metabolomics studies. Metabolites with \(q\) values \(\geq 0.1\) were excluded from further analysis\(^\text{24}\).

Results

A total of nineteen CRC survivors were randomised to a diet intervention group that was either 30 g/d of RB or none (control). In all, twenty-five participants were initially randomised to control \((n = 10)\) or RB \((n = 15)\). Six participants withdrew from the trial due to non-compliance \((n = 5)\) and family emergency \((n = 1)\). No adverse events were reported. Participant characteristics at baseline are presented in the online Supplementary Table S1.

Rice bran modulation of stool metabolite profiles and metabolic pathway networks

The principal component analysis of baseline and 4-week time points revealed inter-individual stool metabolome differences between CRC survivors and minor clustering of individuals after 4 weeks of RB intake (online Supplementary Fig. S2). Table 1 lists ninety-three significant stool metabolites from CRC survivors consuming RB at 4 weeks compared with baseline. Stool metabolites are presented as the mean fold change or mean fold difference with respect to the mean fold change or mean fold difference with respect to the scaled relative abundance of each metabolite for all participants. Of the ninety-three stool metabolites changed with RB consumption, thirty-three metabolites increased and sixty metabolites decreased after 4 weeks (Fig. 1(a) and (b)). \(\beta\)-Hydroxyisovaleroylcarnitine and hydroxybutyrylcarnitine showed a 265-fold and 66-fold increase over time, respectively. In addition, hesperidin (37-fold), apigenin (15-fold), narirutin (15-fold), hesperitin (12-fold), enterodiol (11-fold), diosmetin (5-fold), enterolactone (4-fold), eriocitrin (3-fold) and homostachydrine (1:14-fold) were reflective of increased phytochemical consumption and differentially expressed in the stool metabolome.

Metabolites were classified into metabolic pathway networks and analysed by diet group and time. At 4 weeks, a total of eight metabolic pathways were affected by RB consumption (Fig. 2(a)). Pathways included advanced glycation end product (AGE) pathway impact score of 8.69, steroid metabolism \((5\text{-}04)\), primary bile acid metabolism \((2\text{-}9)\), leucine, isoleucine and valine metabolism \((2\text{-}79)\), methionine, cysteine, S-adenosyl methionine and taurine metabolism \((2\text{-}29)\), inositol metabolism \((2\text{-}17)\), vitamin B\(_6\) metabolism \((2\text{-}17)\) and benzoate metabolism \((2\text{-}0)\) (Fig. 2(a)).

Visual metabolite pathway classification and nodal networks for rice bran consumers

Fig. 3 and 4 display Cytoscape pathway classification nodal network views of the stool metabolic pathways modulated by RB consumption at 4 weeks compared with baseline levels. This visual representation includes metabolites from lipid, cofactor and vitamins metabolic pathways in RB consumers (Fig. 3(a)-(d)). Carbohydrates and amino acid pathways are shown in Fig. 4(a)-(d). Network views confirmed the ninety-three metabolites significantly modulated by RB intake and the suite of metabolites trending towards significance. Fig. 3(a)
| Chemical classes | Metabolic pathway | Metabolite | P     | Fold Change (4 weeks/baseline) |
|------------------|------------------|-----------|-------|------------------------------|
| Amino acid       | Glutathione metabolism | S-methylglutathione | 0.0048 | 0.41 |
|                  | Histidine metabolism | Formiminoglutamate | 0.0127 | 0.21 |
|                  |                  | N-acetylmethionine | 0.0367 | 0.52 |
|                  | Leucine, isoleucine and valine metabolism | β-Hydroxyisovalerylcarnitine | 0.0417 | 264.52 |
|                  |                  | β-Hydroxyisovalerate | 0.033 | 17.91 |
|                  |                  | 4-methyl-2-oxopentanoate | 0.0066 | 0.38 |
|                  |                  | 3-methyl-2-oxobutyrate | 0.0129 | 0.36 |
|                  |                  | 3-methyl-2-oxovalerate | 0.0122 | 0.36 |
|                  |                  | Allo-isoleucine | 0.0005 | 0.31 |
|                  |                  | Ethylmalonate | 0.0475 | 0.71 |
|                  |                  | Isovalerylglucose | 0.0279 | 0.71 |
|                  |                  | N-acetylcysteine | 0.0324 | 0.63 |
|                  | Lysine metabolism | Glutarylcarthamide (C5) | 0.0351 | 48.32 |
|                  |                  | Pipocolate | 0.0232 | 0.49 |
|                  |                  | N6-carboxyethyllysine | 0.0011 | 0.39 |
|                  | Methionine, cysteine, S-adenosyl methionine and taurine metabolism | Cystathionine | 0.0277 | 1.91 |
|                  |                  | N-formylmethionine | 0.0443 | 1.11 |
|                  |                  | N-acetylmethionine | 0.0194 | 0.88 |
|                  |                  | N-acetylmethionine sulfoxide | 0.0043 | 0.47 |
|                  |                  | 4-methylthio-2-oxobutanoate | 0.013 | 0.22 |
|                  | Phenylalanine and tyrosine metabolism | Phenol sulfate | 0.0303 | 4.68 |
|                  |                  | p-cresol sulfate | 0.0376 | 0.69 |
|                  |                  | N-formylphenylalanine | 0.0163 | 0.65 |
|                  |                  | 4-hydroxyphenylpyruvate | 0.0021 | 0.4 |
|                  |                  | Phenylpyruvate | 0.0081 | 0.32 |
|                  | Tryptophan metabolism | Xanthurenic acid | 1.20E-05 | 4.27 |
|                  | Urea cycle; arginine and proline metabolism | Citrulline | 0.0173 | 0.67 |
|                  |                  | N-methylproline | 0.0386 | 0.43 |
|                  |                  | Homocitrulline | 0.0252 | 0.39 |
|                  | Carbohydrate Advanced glycation end product | N6-carboxyethyllysine | 0.0059 | 0.62 |
|                  | Pentose metabolism | Xylitol | 0.0072 | 2.11 |
|                  | Cofactors and vitamins Tocopherol metabolism | γ-Carboxyethyl-hydroxychroman | 0.0243 | 1.78 |
|                  |                  | Vitamin B6 metabolism | Pyridoxine (vitamin B6) | 0.0102 | 2.96 |
|                  | Energy TCA cycle | Aconitate (cis or trans) | 0.0117 | 11.12 |
|                  | Lipid Fatty acid metabolism(acyl carnitine) | Hydroxybutyrylcarnitine* | 0.0106 | 65.96 |
|                  |                  | Hexanoylcarnitine | 0.0306 | 32.74 |
|                  | Fatty acid, dicarboxylate | Hexadecanediol | 0.0042 | 2.07 |
|                  |                  | Sebacate (decanedioate) | 0.0485 | 0.62 |
|                  |                  | Azelate (nonanedioate) | 0.035 | 0.55 |
|                  | Fatty acid, monohydroxy | 2-hydroxyoctanoate | 0.0391 | 0.24 |
|                  |                  | α-Hydroxyoctacaproate | 0.0396 | 0.17 |
|                  | Inositol metabolism | Chiro-inositol | 0.0251 | 26.15 |
|                  | Medium-chain fatty acid | 5-dodecanoate (12:1n-7) | 0.035 | 2.58 |
|                  | Phospholipid metabolism | Ethanolamine | 0.0148 | 1.74 |
|                  |                  | Pelargonate (9:0) | 0.0456 | 0.45 |
|                  | PUFA (n-3 and n-6) | Dihomo-γ-linolenate (20:3n-3 or n-6) | 0.0367 | 0.94 |
|                  | Primary bile acid metabolism Glycochenodeoxycholate | 0.0421 | 0.27 |
|                  |                  | Taurocholate | 0.019 | 0.26 |
|                  | Secondary bile acid metabolism Glycodeoxycholate | 0.0344 | 0.22 |
|                  | Steroid 4-androsten-3β,17β-diol monosulfate (2) | 0.0165 | 9.49 |
|                  |                  | 4-androsten-3β,17β-diol monosulfate (2) | 0.033 | 3.07 |
|                  |                  | 5α-androstan-3β,17β-diol disulfate | 0.0345 | 0.62 |
|                  |                  | 11-ketoetiocholanolone sulfate | 0.0004 | 0.54 |
|                  |                  | Pregnalone/allopregnanolone sulfate | 0.0476 | 0.45 |
|                  |                  | Epiandrosterone sulfate | 0.0289 | 0.41 |
|                  |                  | 4-androsten-3β,17β-diol disulfate (1) | 0.0012 | 0.35 |
|                  |                  | 4-androsten-3β,17β-diol disulfate (2) | 0.0042 | 0.35 |
|                  |                  | 5α-androstan-3β,17β-diol monosulfate (2) | 0.006 | 0.26 |
|                  |                  | 5α-pregnan-3β,20α-diol disulfate | 0.0009 | 0.25 |
|                  |                  | 5α-androstan-3β,17β-diol disulfate | 0.0049 | 0.23 |
|                  |                  | Dehydroisoandrosterone sulfate (DHEA-S) | 0.0013 | 0.22 |
|                  |                  | Pregnenolone sulfate | 0.0109 | 0.21 |
|                  |                  | Pregnen-diol disulfate | 0.0235 | 0.19 |
|                  |                  | 5α-pregnan-3α or 3β,20β-diol disulfate | 0.0112 | 0.14 |
|                  |                  | 16α-hydroxy DHEA 3-sulfate | 0.0086 | 0.14 |
|                  |                  | 4-androsten-3β,17β-diol monosulfate (1) | 0.0142 | 0.13 |
|                  |                  | Pregn sterol monosulfate* | 0.0109 | 0.12 |
|                  | Sterol 4-cholest-ene-3-one | 0.0454 | 0.58 |
and pyridoxine (vitamin B6), which are metabolites in the toco-

inositol had a 26-fold increase after RB consumption. Fig. 3(d) shows the steroid metabolic pathway which was significantly affected after RB consumption with sixteen metabolites significantly decreased. An increase in 4-androsten-3α, 17α-diol monosulfate and 4-androsten-3β, 17β-diol monosulfate were observed. Fig. 3(b) shows primary bile acid metabolism, whereby glycochenodeoxycholate and taurocholate were significantly decreased. Fig. 3(c) displays inositol metabolism whereby chiro-

inositol had a 26-fold increase after RB consumption. Fig. 3(d) showed significant increases in γ-carboxyethyl-hydroxychroman and pyrioxidine (vitamin B6), which are metabolites in the toco-

pheryl and vitamin B6 metabolic pathways, respectively.

Fig. 4(a) showed significantly perturbed AGE metabolism with N6-caboxymethyllysine decreasing 2-fold compared with baseline for the RB group. Fig. 4(b) displays the nine metabolites from the leucine, isoleucine and valine metabolic pathway with significant change in RB consumers compared with baseline (β-hydroxyisovaleroylcarnitine, β-hydroxyisovalerate, 4-methyl-2-oxobutanate, 3-methyl-2-oxobutyrate, 3-methyl-2-oxovalerate, allo-isoleucine, ethylmalonate, isovalerylglycine and N-acetylleucine). Using this pathway visualisation tool, N-acetylvaline (0.64-fold) and N-acetylaspartic acid (0.54-fold) had decreased expression and tiglyl-carnitine (C5:1-DC) (41-fold) increased at 4 weeks, and was trending towards significance compared with baseline in RB consumers. Fig. 4(c) shows the methionine, cysteine, S-adenosyl methionine and taurine metabolic pathways with 4-methylthio-2-oxobutanate, N-acetylthreonine sulfoxide and N-acetylmethionine significantly decreased and cystathionine and N-formylmethionine increased. Fig. 4(d) displays the urea cycle; arginine and proline metabolism pathways and significantly decreased homocitrul-

line, N-methylproline and citrulline metabolites.

**Metabolite profile and pathway distinctions between control and rice bran consumers**

Compared with control diet, thirty-nine stool metabolites (sixteen of which had higher expression in RB consumers) were significantly different in the RB group after 4 weeks of consumption. This includes 28-fold and 14·5-fold increased expression of the phytochemicals hesperidin and nariniritin, respectively, in the stool of RB consumers compared with control diet. Table 2 features nineteen stool metabolites that were also increased in the RB 4 weeks/RB baseline statistical comparison (Table 1). These stool metabolites included lower expression of the phytochemicals hesperidin and nariniritin, phenylalanine, formimoglutamate (5-fold), 4-methyl-2-oxobutanate (3-fold), 3-methyl-2-oxobutyrate (3-fold), 3-methyl-2-oxovalerate (3-fold), allo-isoleucine, ethylmalonate, isovalerylglycine and N-acetylleucine). Using this pathway visualisation tool, N-acetylvaline (0·64-fold) and N-acetylaspartic acid (0·54-fold) had decreased expression and tiglyl-carnitine (C5:1-DC) (41-fold) increased at 4 weeks, and was trending towards significance compared with baseline in RB consumers. Fig. 4(c) shows the methionine, cysteine, S-adenosyl methionine and taurine metabolic pathways with 4-methylthio-2-oxobutanate, N-acetylthreonine sulfoxide and N-acetylmethionine significantly decreased and cystathionine and N-formylmethionine increased. Fig. 4(d) displays the urea cycle; arginine and proline metabolism pathways and significantly decreased homocitrul-

line, N-methylproline and citrulline metabolites.

| Chemical classes | Metabolic pathway | Metabolite | Fold Change | P   |
|------------------|------------------|------------|-------------|-----|
| Peptide          | γ-Glutamyl amino acid | γ-Glutamylphenylalanine | 0·0428 | 1·02↑ |
| Other            | Xenobiotic       | 2-hydroxyhippurate (salicylurate) | 3·38E–05 | 8·75↑ |
|                  |                  | 3-(2-hydroxyphenyl)propionate | 0·0386 | 3·04↑ |
|                  |                  | p-aminobenzoate (PABA) | 0·0485 | 0·58↓ |
| Phytochemical     |                  | 2-oxo-1-pyrolidinepropionate | 0·0435 | 0·82↓ |
|                  |                  | 3-aminobutyrate | 0·045 | 0·64↓ |
|                  |                  | Brilliant blue FCF (blue 1) | 0·0492 | 0·17↓ |
|                  |                  | Diosmin | 0·0018 | 6·89↑ |
|                  |                  | Salicylate | 0·0417 | 2·56↑ |
|                  |                  | Metoprol acid metabolite* | 0·0103 | 0·78↑ |
|                  |                  | Ranitidine | 0·01 | 0·41↓ |
|                  |                  | Hesperidin | 0·0017 | 37·21↑ |
|                  |                  | Apigenin | 0·0002 | 15·32↑ |
|                  |                  | Narirutin | 0·0089 | 14·53↓ |
|                  |                  | Hesperetin | 0·0329 | 12·08↑ |
|                  |                  | Enterodiol | 0·0013 | 11·33↑ |
|                  |                  | Diosmetin | 0·0347 | 5·13↑ |
|                  |                  | Enterolactone | 0·0015 | 3·65↓ |
|                  |                  | Eriocitrin | 0·0114 | 2·72↑ |
|                  |                  | Homostachydrine* | 0·0356 | 1·14↑ |
|                  |                  | Abscisic acid | 0·0475 | 0·53↓ |
|                  |                  | Capsaicin | 0·0135 | 0·49↓ |
|                  |                  | Harmine | 0·0407 | 0·39↓ |
|                  |                  | Methyl indole-3-acetate | 0·0082 | 0·2↓ |
|                  |                  | Solanidine | 4·98E–05 | 0·63↓ |

1. Metabolites with significantly (P ≤ 0·05) higher expression in rice bran consumers at 4 weeks when compared with rice bran consumers at baseline (metabolite ratio of ≥ 1·00); 1. Metabolites with significantly (P ≤ 0·05) lower expression in rice bran consumers at 4 weeks when compared with rice bran consumers at baseline (metabolite ratio of <1·00). * Compounds that have not been officially confirmed based on a standard, but we are confident in its identity.
Fig. 1. Stool metabolite profile differences in the rice bran group over time. (a) Stool metabolites that were significantly different between 4-week and baseline time points with fold change values ≥5·00 and (b) stool metabolites that were significantly different between 4-week and baseline time points and had fold change values <5·00. *, Metabolites with significance and were identified in the rice bran food metabolome (see online Supplementary Table S3).
There was modulation of eight metabolic pathways between RB and control diet consumers at 4 weeks. Fig. 2(b) shows fatty acid metabolism (pathway impact score of 10.36), leucine, isoleucine and valine metabolism (5.18), vitamin B₆ metabolism (5.18), aminosugar metabolism (4-6), drug metabolism (3-55), medium-chain fatty acid (2-3) and glycine, serine and threonine metabolism (2.07).

There were forty-one metabolites with significant stool metabolome differences between CRC survivors consuming a control diet at 4 weeks compared with baseline. These control diet modifications in stool are listed in the online Supplementary Table S2. Increased 3-(2-hyroxyphenyl)propionate, salicylate, apigenin and enterolactone and decreased abscisate were observed among both diet groups at 4 weeks. N6-carboxymethyllysine showed increased relative abundance after 4 weeks of consumption in control diet consumers, and a decreased relative abundance in RB consumers (Table 1 and online Supplementary Table S2).

**Rice bran food metabolome**

The RB food metabolome demonstrates extensive phytochemical diversity and provides an opportunity to look for cross-over with the stool metabolome, following consumption. The RB food metabolome was analysed for comparison with stool metabolite profiles. There were 453 metabolites identified from RB that were classified into seventy-four metabolic pathways. The online Supplementary Table S3 lists the RB metabolites and the metabolic pathway classifications identified in the stool of the RB group. Additional details on the RB metabolome can be found in Zarei et al.([28]).

**Overlap between the stool and rice bran food metabolomes**

The thirty-nine significantly changed stool metabolites from RB consumers that were also present in the RB food metabo-lome are shown in Fig. 1(a) and (b). These included

---

Fig. 2. Pathway set enrichment scores for stool metabolome. (a) Metabolic pathways in rice bran over time that were significantly different between 4-week and baseline time points and (b) rice bran diet compared with control diet at 4 weeks. Pathway set enrichment scores were determined as defined in the ‘Methods’ section, and are presented for pathways with scores ≥2. SAM, S-adenosyl methionine.
Rice bran modifies stool metabolome in adults

N6-carboxymethyllysine, an AGE, which decreased by 2-fold in RB consumers’ stool over 4 weeks. Apigenin (15-fold increased) and abscisate (2-fold decreased) were also present in the RB food metabolome, as well as the inositol metabolite chiro-inositol, which increased 26-fold over time in the RB stool metabolome. Xanthurenic acid, a tryptophan metabolite, increased 4-fold in stool after RB consumption and was present in the RB. Pyridoxine was another metabolite involved in vitamin B6 metabolism that increased in stool and was present in RB. Fatty acids azelate (nonamediate) (2-fold decreased), hexadecanediolate (2-fold increased), sebacate (decanedioate) (2-fold decreased), 2-hydroxyoctanoate (4-fold decreased) and α-hydroxypropionate (6-fold decreased) also had dual significance for presence in the RB food metabolome (Fig. 1). Furthermore, 2-hydroxyxiphippurate (salicylate) was expressed in the RB food metabolome, as well as after 4 weeks of RB consumption and when compared with the control diet.

Fig. 3. Stool metabolomic pathway network analysis of lipid, cofactor and vitamin metabolites significantly different in rice bran consumers at 4 weeks compared with baseline. Pathway specific network views (Cytoscape) are presented for (a) steroid metabolism, (b) primary bile acid metabolism, (c) inositol metabolism, (d) cofactors and vitamin metabolism. Each metabolite is represented as a node, extending from a central metabolic pathway (with pathway impact score). A pathway set enrichment score ≥2 implies that pathway contains more metabolites of statistical significance relative to the entire study. The size of a node is proportional to the fold change between baseline and 4-week time points. A node colour red represents metabolites with significantly (P ≤ 0.05) higher expression at 4 weeks compared with baseline. A node colour dark green represents metabolites with significantly lower expression at 4 weeks compared with baseline. Nodes colour pink or light green represent metabolites trending towards significance (0.05 > P > 0.1) with higher expression at 4 weeks and lower expression at 4 weeks, respectively. CEHC, carboxyethyl-hydroxychroman.
Discussion

The primary objective of this study was to understand the stool metabolite profile differences between CRC survivors consuming a diet supplemented with RB for 4 weeks compared with a control group. These findings revealed that the consumption of RB leads to significant up-regulation of molecules from the carbohydrate, lipid, amino acid and cofactors and vitamin metabolic pathways in CRC survivors (Fig. 2–4). The ninety-three stool metabolites and eight metabolic pathways analysed within the context of the RB food metabolome may have functional potential for dietary chemoprevention and inform nutritional intakes in CRC survivors. Furthermore, multiple stool metabolites that originate from consumption of RB phytochemicals were identified.

Two stool metabolites with the highest degree of fold change between baseline and 4-week time points in RB consumers were β-hydroxyisovaleroylcarnitine and β-hydroxyisovalerate (a 265-fold and 18-fold, increase after consumption, respectively). Currently, no data have been published on β-hydroxyisovaleroylcarnitine and cancer, including CRC and limited data exists for β-hydroxyisovalerate. β-Hydroxyisovalerate has been used as a biomarker for lung cancer in a urinary metabolomics study. This compound is closely related to

---

Fig. 4. Stool metabolomic pathway network analysis of carbohydrate and amino acid metabolites significantly different in rice bran consumers at 4 weeks compared with baseline. Pathway specific network views (Cytoscape) are presented for (a) advanced glycation end product metabolism, (b) leucine, isoleucine and valine metabolism, (c) methionine, cysteine, S-adenosyl methionine (SAM) and taurine metabolism, (d) urea cycle; arginine and proline metabolism. Each metabolite is represented as a node, extending from a central metabolic pathway (with pathway impact score). A pathway set enrichment score $\geq 2$ implies that pathway contains more metabolites of statistical significance relative to the entire study. The size of a node is proportional to the fold change between baseline and 4-week time points. A node coloured red represents metabolites with significantly ($P \leq 0.05$) higher expression at 4 weeks compared with baseline. A node coloured dark green represents metabolites with significantly lower expression at 4 weeks compared with baseline. Nodes coloured pink or light green represent metabolites trending towards significance ($0.05 < P \leq 0.1$) with higher expression at 4 weeks and lower expression at 4 weeks, respectively.
Table 2. Stool metabolites distinguishing rice bran (n 9) and control diet (n 10) groups at 4 weeks

| Super pathways       | Metabolic pathway            | Metabolite                             | Control relative abundance | Rice bran relative abundance | P     | Fold difference (rice bran/ control) |
|----------------------|------------------------------|----------------------------------------|-----------------------------|-----------------------------|-------|--------------------------------------|
| Amino acid           | Glycine, serine and threonine metabolism | Allo-threonine                         | 3.372                      | 0.5938                      | 0.0201| 0.181†                               |
| Histidine metabolism | Formimoglutamate              | 2.6375                                 | 0.5649                     | 0.0159                      | 0.110 |                              |
| Leucine, isoleucine and valine metabolism | Methylsuccinate              | 1.6559                                 | 1.4789                     | 0.0429                      | 1.87† |                              |
|                     | 4-methyl-2-oxopentanoate      | 1.7672                                 | 0.6899                     | 0.0044                      | 0.29† |                              |
|                     | 3-methyl-2-oxobutyrate        | 1.8088                                 | 0.654                       | 0.0083                      | 0.23† |                              |
|                     | 3-methyl-2-oxovalerate        | 1.7205                                 | 0.6219                     | 0.0044                      | 0.42† |                              |
| N-acetylserine       | 1.7169                       | 0.9344                                 | 0.0388                      | 0.184                       |       |                              |
| N-acetylleucine      | 1.265                        | 0.7912                                 | 0.0376                      | 0.15†                       |       |                              |
| Allo-isoleucine      | 2.5098                       | 0.7683                                 | 0.0181                      | 0.11†                       |       |                              |
| Lysine metabolism    | 2-amino adipate               | 1.5763                                 | 1.1657                     | 0.0192                      | 1.68† |                              |
| Methionine, cysteine, S-adenosyl methionine and taurine metabolism | 4-methylthio-2-oxobutanate | 0.8167                                 | 0.1811                     | 0.0073                      | 0.06† |                              |
| Phenylalanine and tyrosine metabolism | 4-hydroxyphenylpyruvate     | 1.3693                                 | 0.5473                     | 0.0032                      | 0.31† |                              |
| Tryptophan metabolism | Phenylpyruvate               | 1.643                                  | 0.5299                     | 0.0017                      | 0.19† |                              |
| Urea cycle; arginine and proline metabolism | Xanthurenic acid           | 0.3761                                 | 1.1607                     | 2.85E-05                    | 10.8† |                              |
|                      | N-acetylglutaminic acid       | 0.6907                                 | 0.3838                     | 0.0016                      | 0.25† |                              |
| Carbohydrate         | Aminosugar metabolism        | N-acetylgalactosamine                  | 0.5458                     | 0.4927                      | 0.0422| 0.2†                                |
|                      | N-acetylgalactosamine         | 0.8465                                 | 1.1016                     | 0.0497                      | 0.3†  |                              |
| Cofactors and vitamins | Vitamin B6 metabolism       | Pyridoxine (vitamin B6)               | 2.3113                     | 6.8453                      | 0.0034| 6.74†                              |
| Lipid               | Fatty acid metabolism(acyl glycerol) | Valerylglutamic acid                  | 1.1844                     | 0.8156                      | 0.0285| 0.12†                              |
|                     | Heptanoyl glycerol            | 0.0201                                 | 0.0201                     | 0.0198                      | 0.02† |                              |
|                     | Hexanoylglutamic acid         | 0.8351                                 | 0.5023                     | 0.0461                      | 0.02† |                              |
| Fatty acid, amino    | 2-aminooctanoate              | 0.5119                                 | 0.4718                     | 0.0309                      | 0.17† |                              |
| Lysolipid           | 1-stearylglucosylglycerophosphate (18:0) | 0.413                                 | 0.7588                     | 0.0307                      | 0.07† |                              |
| Medium-chain fatty acid | 10-undecenoic acid (11:1n-1) | 0.6558                                 | 0.5173                     | 0.0001                      | 0.30† |                              |
| Monoacylglycerol     | 2-stearylglucosylglycerophosphate (2-monostearin) | 0.9148                             | 1.1027                     | 0.036                        | 0.54† |                              |
| PUFA (n-3 and n-6)  | Docosadienoic acid (22:2n-6)  | 0.8616                                 | 1.2862                     | 0.0149                      | 0.24† |                              |
| Nucleotide          | Pyrimidine metabolism, uracil containing | 5-hydroxymethyluracil | 0.1535                     | 0.3954                     | 0.0488 | 2.58†                           |
| Other               | Xenobiotics                   | 2-hydroxyethylpyruvate (salicylate)   | 0.4121                     | 3.6062                      | 1.47E-05 | 3.75† |
|                     | Metoprolol                    | 0.46                                   | 0.4479                     | 0.0361                      | 73.43† |                              |
|                     | Dosimic                      | 0.0974                                 | 0.6707                     | 0.0021                      | 6.48† |                              |
|                     | Farnotidine                  | 0.0666                                 | 0.3476                     | 0.0488                      | 4.01† |                              |
|                     | Diltaizem                    | 0.3985                                 | 0.5704                     | 0.0488                      | 1.43† |                              |
|                     | Methotrexate                 | 0.7719                                 | 0.8371                     | 0.0488                      | 1.08† |                              |
|                     | Fluoxetine                   | 0.4939                                 | 0.6136                     | 0.0488                      | 1.06† |                              |
| Phytochemical        | Hesperidin                   | 0.3687                                 | 13.7199                    | 0.0026                      | 28.44† |                              |
|                     | Narirutin                    | 0.0307                                 | 0.4461                     | 0.0032                      | 14.53† |                              |
|                     | Diosmetin                    | 0.2638                                 | 1.3527                     | 0.035                        | 3.97† |                              |
|                     | Eriocitrin                   | 0.2541                                 | 0.6921                     | 0.0044                      | 2.72† |                              |
|                     | Solanidene                   | 2.5996                                 | 0.0778                     | 0.016                        | 0.03† |                              |

† Metabolites with significantly (P≤0.05) higher expression in rice bran consumers at 4 weeks when compared with control at 4 weeks (metabolite ratio of ≥1.00); † Metabolites with significantly (P≤0.05) lower expression in rice bran consumers at 4 weeks when compared with control at 4 weeks (metabolite ratio of <1.00).
represents a diet modifiable biomarker of RB intake in CRC survivors and should be confirmed with a targeted investigation in a larger cohort.

Phytochemicals related to citrus intake include hesperidin, eriocitrin and narirutin were significantly increased over time with RB consumption. Hesperidin has shown to alleviate oxidative stress and down-regulate proinflammatory markers in azoxymethane-induced colon carcinogenesis in mice(56). Eriocitrin has shown significance in multiple analyses and has anti-inflammatory properties in vitro(57). Narirutin, has evidence for anti-inflammatory(38), anti-inflammatory(39) and anti-allergic activities(40). These three compounds were increased with RB diet consumption in our study and may be related to RB metabolism changes by the host. Solanidine, a phytochemical of importance to CRC survivors, is a steroidal alkaloid that has anticancer activities against human colon HCT-8 and HT-29 cancer cells(41). The phytochemical diosmetin and a closely related microbota metabolism-driven derivative, diasmin, have shown oxidative activity against cancer cells (Colon205), inducing apoptosis in Colo320 CRC cells, as well as reducing the multiplicity of CRC neoplasms in azoxymethane-treated mice(42,43). Phytochemical modulation and host metabolites in stool following RB consumption represents a novel chemopreventive mechanism that should be further explored.

6-carboxymethyllysine is an AGE which are a group of heterogeneous macromolecules that are formed by the non-enzymatic glycation of proteins, lipids and nucleic acids(44). There are two main sources of AGE in humans: food and endogenously produced exposures(45). AGE are typically generated in higher rates in diabetics due to altered glucose metabolism(46). In our study, 6-carboxymethyllysine was decreased with RB consumption over time and increased in control diet consumers at 4 weeks, which is consistent with rice bran and whole grain brown rice having the ability to lower glucose and serum lipids in Type I and II diabetics(47–49).

Another stool metabolite of importance to diabetes control and CRC prevention is 2-hydroxyisovalerate (salicylate). This compound increased by 9-fold following RB consumption after 4 weeks, and had an increased fold change of 3.75 compared with control at 4 weeks (Tables 1 and 2). 2-hydroxyisovalerate (salicylate) is a metabolite of aspirin, and has not only shown the ability to prevent CVD complications in diabetes mellitus patients, but also has demonstrated high efficacy in reducing incidence of colorectal neoplasias(50–52). Moreover, faecal 2-hydroxyisovalerate (salicylate) levels were associated with a decreased risk of CRC in a prior faecal metabolomics investigation(53). Therefore, we postulate that decreased AGE and increased 2-hydroxyisovalerate (salicylate) levels in stool due to RB consumption represent potential mechanisms for chemoprevention. This dietary compound has relevance as candidate markers of glucose, lipid and xenobiotic metabolism changes.

The individual metabolites, as well as the network of metabolic pathways that were modulated by RB consumption, identified primary bile acid metabolism with a pathway impact score of 2.9. Primary bile acids included glycochenodeoxycholate and taurocholate that were decreased nearly 4-fold in stool after 4 weeks of RB consumption. In addition, there was a 5-fold decreased expression of glycodeoxycholate, a secondary bile acid. Primary bile acids are synthesised by the human liver and undergo transformation to secondary bile acids by the microbiota(54). Secondary bile acids have associations with reactive O2/N species generation and oxidative DNA damage(55). The reduction of bile acid metabolites (primary and secondary) in the stool metabolome of CRC survivors is consistent with healthy adults(15) and was identified as a novel mechanism for RB chemoprevention that should be further explored.

Nutrition-based therapies have proven effective for improving long-term prognosis in CRC patients(56,57). Increasing dietary fibre has been inversely correlated with CRC risk(58), and RB represents a rich source of dietary fibre that can be successfully incorporated into the diet(15,21,22). This unique metabolome analytical approach was to dually investigate the stool metabolite profiles and RB food metabolome, where the online Supplementary Table S3 illustrates the thirty-nine metabolites identified in both the RB metabolome and stool metabolome of RB consumers. β-Hydroxyisovalerate and pyridoxine represent two metabolites of potential dietary biomarkers of RB intake and identified in stool. Foodomics is a branch of metabolomics aimed at quantifying metabolite intakes and to correlate these exposures with biomarkers and health benefits(59). The combined foodomics and stool metabolomics analytical approach with CRC survivors led to the identification metabolic pathway networks associated with dietary chemoprevention. Major strengths of this study were the confident metabolite identifications from a non-targeted stool and RB food metabolomics analysis. Study limitations included low sample size and high inter-group variation across individuals. Based on these results, we postulate that urine and blood matrices merit a similar analytical integration to determine specific, sensitive biomarkers of food intake and biological accessibility. The compelling findings from this subset of individuals included in this investigation provide rationale for RB consumption in larger studies and over longer periods of time to further analyse dietary biomarkers of intake, as well as to identify biomarkers of CRC recurrence and prevention, particularly in the colon tissue. Our findings demonstrate that the integration of food and stool metabolomes is useful for understanding dietary chemopreventive mechanisms for CRC prevention and control.

**Acknowledgements**

The authors would like to acknowledge the University of Colorado Health – North Oncology Research group, specifically Joann Lovins, Erica Dickson, Joanne O’Malia and Marlon Bazan, for helping with regulatory approvals, assistance with study recruitment, implementation, consents and coordination of sample collection. The authors thank Dr Anna McClung from the US Department of Agriculture for supplying the study intervention heat-stabilised rice bran; Dr Tiffany Weir for assistance in study design, food preparation and stool collection; and Iman Zarei for helping with proofreading. Katie Schmitz, Genevieve Forster, Allie Reava, Kerry Gundlach and
Rice bran modifies stool metabolome in adults

12. Phuthaphadoong S, Yamada Y, Hirata A, et al. (2010) Chemopreventive effect of fermented brown rice and rice bran (FBRA) on the inflammation-related colorectal carcinogenesis in ApcMin/+ mice. Oncol Rep 23, 53–59.

13. Islam MS, Nagasaka R, Ohara K, et al. (2011) Biological abilities of rice bran-derived antioxidant phytochemicals for medical therapy. Curr Top Med Chem 11, 1847–1853.

14. Sun W, Xu W, Liu H, et al. (2009) Gamma-tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells. J Nutr Biochem 20, 276–284.

15. Shellen AM, Borresen EC, Wdowik MJ, et al. (2015) Pilot dietary intervention with heat-stabilized rice bran modulates stool microbiota and metabolites in healthy adults. Nutrients 7, 1282–1300.

16. Martinez I, Lattimer JM, Hubsch KL, et al. (2013) Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J 7, 269–280.

17. Komiyama Y, Andoh A, Fujitaya D, et al. (2011) New prebiotics from rice bran ameliorate inflammation in murine colitis models through the modulation of intestinal homeostasis and the mucosal immune system. Scand J Gastroenterol 46, 40–52.

18. Schmidt CG, Goncalves LM, Prietto I, et al. (2014) Antioxidant activity and enzyme inhibition of phenolic acids from fermented rice bran with fungus Rizhopus oryzae. Food Chem 146, 371–377.

19. Hullar MA, Burnett-Hartman AN & Lampe JW (2014) Gut microbes, diet, and cancer. Cancer Treat Res 159, 377–399.

20. Ryan EP, Heuberger AL, Weir TL, et al. (2011) Rice bran fermented with Saccharomyces boulardii generates novel metabolite profiles with bioactivity. J Agric Food Chem 59, 1862–1870.

21. Borresen EC, Brown DG, Harbison G, et al. (2016) A randomized controlled trial to increase navy bean or rice bran consumption in colorectal cancer survivors. Nutr Cancer 68, 1269–1280.

22. Shellen AM, Borresen EC, Kirkwood JS, et al. (2016) Dietary supplementation with rice bran or navy bean alters gut bacterial metabolism in colorectal cancer survivors. Mol Nutr Food Res (Epublication ahead of print version 12 September 2016).

23. Heuberger AL, Lewis MR, Chen MH, et al. (2010) Metabolomic and functional genomic analyses reveal varietal differences in bioactive compounds of cooked rice. PloS ONE 5, e12095.

24. Brown DG, Rao S, Weir TL, et al. (2016) Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab 4, 1–12.

25. Evans AM, DeHaven CD, Barrett T, et al. (2009) Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81, 6656–6667.

26. Nyanamanda G, Gormley IC, Fan Y, et al. (2013) MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinformatics 14, 338.

27. Blaise BJ (2013) Data-driven sample size determination for metabolic phenotyping studies. Antal Chem 85, 8943–8950.

28. ZarcI I, Brown DG, Nealon NJ, et al. (2017) Rice bran metabolome contains amino acids, vitamins, cofactors, and phytochemicals with medicinal and nutritional properties. Rice. doi:10.1186/s12284-017-0157-2.

29. Silva C, Cavaco C, Perestrello R, et al. (2014) Microextration by packed sorbent (MEPS) and solid-phase microextraction (SPME) as sample preparation procedures for the metabolomic profiling of urine. Metabolites 4, 71–97.
1256 D. G. Brown et al.

30. Fukui Y & Itoh K (2010) A plasma metabolomic investigation of colorectal cancer patients by liquid chromatography-mass spectrometry. *Open Aniul Clin Res* 4, 1–9.

31. Mock NI, Malik MI, Stumbo PJ, et al. (1997) Increased urinary excretion of 3-hydroxyisovaleric acid and decreased urinary excretion of biotin are sensitive early indicators of decreased biotin status in experimental biotin deficiency. *Am J Clin Nutr* 65, 951–958.

32. Clayton PT (2006) B6-responsive disorders: a model of vitamin B6 intake and the risk of colorectal cancer. *Epidemiol Biomarkers and Prevention* 17, 62–66.

33. Levy G (1980) Clinical pharmacokinetics of salicylates: a re-assessment. *Br J Clin Pharmacol* 10, Suppl. 2, 285S–290S.

34. Garcia-Albeniz X & Chan AT (2011) Aspirin for the prevention of colorectal cancer. *Best Pract Res Clin Gastroenterol* 25, 461–472.

35. Pignone M, Alberts MJ, Colwell JA, et al. (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. *Circulation* 121, 2694–2701.

36. Goedert JJ, Sampson JN, Moore SC, et al. (2014) Fecal metabolomics: assay performance and association with colorectal cancer. *Carcinogenesis* 35, 2089–2096.

37. Sayin SI, Wahlstrom A, Felin J, et al. (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metab* 17, 225–235.

38. Payne CM, Bernstein C, Dvorak K, et al. (2008) Hydrophobic bile acids, genomic instability, Darwinian selection, and colorectal cancer. *Clin Exp Gastroenterol* 1, 19–47.

39. Rasvaco P, Monteiro-Grillo I & Camila M (2012) Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. *Am J Clin Nutr* 96, 1346–1353.

40. Rasvaco P, Monteiro-Grillo I, Vidal PM, et al. (2005) Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. *J Clin Oncol* 23, 1431–1438.

41. Dahm CC, Keogh RH, Lentjes MAH, et al. (2010) Intake of dietary fats and colorectal cancer risk: prospective findings from the UK Dietary Cohort Consortium. *Cancer Epidemiol Biomarkers Prev* 19, 562–567.

42. Spanish Cancer Research Group (2009) Cytotoxic activity of flavonoids from the flowers of Chrysanthemum coronarium on human colon cancer Colon205 cells. *J Asian Nat Prod Res* 11, 771–778.

43. Zheng Q, Hirose Y, Yoshimi N, et al. (2002) Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. *J Cancer Res Clin Oncol* 128, 539–546.

44. Fu MX, Requena JR, Jenkins AJ, et al. (1996) The advanced glycation end product, Nε-carboxymethyllysine, is a product of both lipid peroxidation and glycoxidation reactions. *J Biol Chem* 271, 9982–9986.

45. Uralp N, Woodruff S, Goodman S, et al. (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. *Am J Med Diet Assoc* 110, 911–916 e912.

46. Ahmed N (2005) Advanced glycation end products – role in pathology of diabetic complications. *Diabetes Res Clin Pract* 67, 3–21.

47. Kim TH, Kim EK, Lee MS, et al. (2011) Intake of brown rice lees reduces waist circumference and improves metabolic parameters in type 2 diabetes. *Nutr Res* 31, 131–138.

48. Qureshi AA, Sami SA & Khan FA (2002) Effects of stabilized rice bran, its soluble and fiber fractions on blood glucose levels and serum lipid parameters in humans with diabetes mellitus Types I and II. *J Nutr Biochem* 13, 175–187.

49. C Chou TW, Ma CY, Cheng HH, et al. (2009) A rice bran oil diet improves lipid abnormalities and suppress hyperinsulinemic responses in rats with streptozotocin/nicotinamide-induced type 2 diabetes. *J Clin Biochem Nutr* 45, 29–36.